$RVMD
Revolution Medicines, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022008496 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $9.116M $7.578M $9.460M
YoY Change 4.81% -25.2% 8.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.20M $9.037M $8.692M
YoY Change 39.84% 35.49% 49.09%
% of Gross Profit
Research & Development $61.00M $56.49M $53.68M
YoY Change 32.8% 38.26% 45.04%
% of Gross Profit
Depreciation & Amortization $1.198M $901.0K $1.083M
YoY Change 12.07% 34.28% 15.21%
% of Gross Profit
Operating Expenses $71.21M $65.53M $62.37M
YoY Change 55.01% 37.87% 45.63%
Operating Profit -$62.09M -$57.95M
YoY Change 39.42% 54.96%
Interest Expense $867.0K $0.00 $237.0K
YoY Change 267.37% -100.0% -1.25%
% of Operating Profit
Other Income/Expense, Net $867.0K $302.0K
YoY Change 267.37% 36.65%
Pretax Income -$61.22M -$57.65M -$52.68M
YoY Change 38.2% 55.07% 55.66%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$61.22M -$57.65M -$52.68M
YoY Change 38.2% 55.07% 54.01%
Net Earnings / Revenue -671.59% -760.72% -556.83%
Basic Earnings Per Share -$0.82 -$0.78
Diluted Earnings Per Share -$824.2K -$777.3K -$713.6K
COMMON SHARES
Basic Shares Outstanding 74.25M 74.19M
Diluted Shares Outstanding 74.28M 74.16M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $461.4M $518.8M $577.1M
YoY Change -28.61% -23.89% 30.94%
Cash & Equivalents $105.8M $97.67M $108.5M
Short-Term Investments $355.7M $421.1M $468.6M
Other Short-Term Assets $15.99M $10.21M $6.790M
YoY Change 95.9% 24.46% -3.0%
Inventory
Prepaid Expenses
Receivables $5.624M $5.383M $5.929M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $483.0M $534.3M $589.8M
YoY Change -26.92% -23.38% 29.87%
LONG-TERM ASSETS
Property, Plant & Equipment $73.34M $13.06M $11.54M
YoY Change 582.65% -65.28% 29.68%
Goodwill $14.61M $14.61M
YoY Change 0.0%
Intangibles $59.61M $59.88M
YoY Change -1.75%
Long-Term Investments
YoY Change
Other Assets $2.462M $851.0K $758.0K
YoY Change 82.64% -39.21% 148.52%
Total Long-Term Assets $149.8M $148.4M $148.2M
YoY Change 32.49% 29.86% 30.84%
TOTAL ASSETS
Total Short-Term Assets $483.0M $534.3M $589.8M
Total Long-Term Assets $149.8M $148.4M $148.2M
Total Assets $632.8M $682.8M $738.0M
YoY Change -18.25% -15.88% 30.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.07M $14.17M $14.06M
YoY Change 34.81% 46.12% 11.48%
Accrued Expenses $39.14M $31.57M $33.62M
YoY Change 45.34% 31.55% 50.11%
Deferred Revenue $11.43M $12.36M
YoY Change 14.74% 2.04%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $63.54M $57.46M $60.35M
YoY Change 38.73% 31.31% 27.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $62.98M $1.634M $634.0K
YoY Change 75.94% 13.55% 0.32%
Total Long-Term Liabilities $62.98M $1.634M $634.0K
YoY Change 75.94% 13.55% 0.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.54M $57.46M $60.35M
Total Long-Term Liabilities $62.98M $1.634M $634.0K
Total Liabilities $134.0M $131.8M $135.4M
YoY Change 50.45% 47.95% 46.04%
SHAREHOLDERS EQUITY
Retained Earnings -$510.3M -$452.6M
YoY Change 68.57% 70.46%
Common Stock $1.063B $1.056B
YoY Change 3.64% 42.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $498.8M $551.0M $602.6M
YoY Change
Total Liabilities & Shareholders Equity $632.8M $682.8M $738.0M
YoY Change -18.25% -15.88% 30.06%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$61.22M -$57.65M -$52.68M
YoY Change 38.2% 55.07% 54.01%
Depreciation, Depletion And Amortization $1.198M $901.0K $1.083M
YoY Change 12.07% 34.28% 15.21%
Cash From Operating Activities -$55.72M -$55.16M -$39.27M
YoY Change 63.5% 48.1% 56.87%
INVESTING ACTIVITIES
Capital Expenditures -$2.526M $1.889M -$1.183M
YoY Change 92.68% -47.22% 1.11%
Acquisitions
YoY Change
Other Investing Activities $64.93M $45.91M $9.716M
YoY Change -153.45% 679.52% -84.85%
Cash From Investing Activities $62.40M $44.03M $8.533M
YoY Change -150.82% 1806.67% -86.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.429M 305.0K 10.73M
YoY Change 63.88% -99.89% 620.0%
NET CHANGE
Cash From Operating Activities -55.72M -55.16M -39.27M
Cash From Investing Activities 62.40M 44.03M 8.533M
Cash From Financing Activities 1.429M 305.0K 10.73M
Net Change In Cash 8.114M -10.83M -20.00M
YoY Change -105.2% -104.38% -150.76%
FREE CASH FLOW
Cash From Operating Activities -$55.72M -$55.16M -$39.27M
Capital Expenditures -$2.526M $1.889M -$1.183M
Free Cash Flow -$53.19M -$57.05M -$38.08M
YoY Change 62.33% 39.74% 59.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001628171
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2055
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74245139
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97667000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108497000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
421087000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
468557000
CY2022Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5383000
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5929000
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39219
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Revolution Medicines, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2029180
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
700 Saginaw Drive
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94063
CY2022Q1 dei City Area Code
CityAreaCode
650
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
481-6801
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value per Share
CY2022Q1 dei Trading Symbol
TradingSymbol
RVMD
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10206000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6790000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
534343000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
589773000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13056000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11544000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58570000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59692000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59609000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59876000
CY2022Q1 us-gaap Goodwill
Goodwill
14608000
CY2021Q4 us-gaap Goodwill
Goodwill
14608000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1737000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1737000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
851000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
758000
CY2022Q1 us-gaap Assets
Assets
682774000
CY2021Q4 us-gaap Assets
Assets
737988000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
14174000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14057000
CY2022Q1 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
25520000
CY2021Q4 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
27721000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6331000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6214000
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11433000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12358000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
57458000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
60350000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
5662000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
6573000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7444000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
7444000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59583000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60419000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1634000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
634000
CY2022Q1 us-gaap Liabilities
Liabilities
131781000
CY2021Q4 us-gaap Liabilities
Liabilities
135420000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74227672
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74227672
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74142619
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74142619
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1062552000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1055572000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1284000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-376000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-510283000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-452636000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
550993000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
602568000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
682774000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
737988000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7578000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10131000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56490000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40858000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9037000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6670000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
65527000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
47528000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57949000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37397000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
302000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
233000
CY2022Q1 us-gaap Interest Expense
InterestExpense
0
CY2021Q1 us-gaap Interest Expense
InterestExpense
12000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
302000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
221000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57647000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37176000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-57647000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-37176000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74162363
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70420076
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-57647000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-37176000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-908000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-53000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58555000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37229000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
602568000
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
58122
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
305000
CY2022Q1 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
31000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6644000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-908000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-57647000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
550993000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
474676000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
281145000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
555000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-670000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
114000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1031000
CY2021Q1 rvmd Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfStockOptions
46000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3387000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-53000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-37176000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
722580000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-57647000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-37176000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-19000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
267000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
267000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6644000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3387000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
901000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
671000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-648000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-534000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1122000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
740000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-546000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1171000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3416000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1257000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-492000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2131000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2114000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1200000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1836000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2493000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-719000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
853000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55160000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37246000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
111818000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
114038000
CY2022Q1 rvmd Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
157732000
CY2021Q1 rvmd Proceeds From Maturity Of Marketable Securities
ProceedsFromMaturityOfMarketableSecurities
119926000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1889000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3579000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44025000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2309000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
281709000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
305000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
555000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
305000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
282264000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10830000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
247327000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110234000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105352000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
99404000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
352679000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97667000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
351595000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1737000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
1084000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99404000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
352679000
CY2022Q1 rvmd Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
31000
CY2021Q1 rvmd Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
46000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1672000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
882000
CY2022Q1 rvmd Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
89000
CY2021Q1 rvmd Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
564000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-510300000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, clinical accruals, valuation of in-process research and development and developed technologies, income taxes, useful lives of property and equipment and intangible assets, impairment of goodwill and intangibles, the incremental borrowing rate for determining operating lease assets and liabilities and stock-based compensation. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and there was not a material impact to the Company’s condensed consolidated financial statements as of and for the three months ended March 31, 2022. Actual results could materially differ from the Company’s estimates, and there may be changes to the estimates in future periods</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span>
CY2022Q1 rvmd Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
0
CY2021Q4 rvmd Fair Value Level1 Level2 Level3 Transfers Amount
FairValueLevel1Level2Level3TransfersAmount
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
520731000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1305000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
519447000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
578322000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
377000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
577946000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
520731000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
21000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1305000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
519447000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24613000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22356000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11557000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10812000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13056000
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7480000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3671000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3809000
CY2022Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y7M6D
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
63280000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3671000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59609000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11544000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2022Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4250000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9852000
CY2022Q1 rvmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
19953000
CY2021Q4 rvmd Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
17018000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1037000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
540000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
280000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
311000
CY2022Q1 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
25520000
CY2021Q4 rvmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
27721000
CY2022Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
802000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1069000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1069000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
869000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3809000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
55800000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7480000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3404000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4076000
CY2021 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y10M24D
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
63280000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3404000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
59876000
CY2021Q4 us-gaap Goodwill
Goodwill
14608000
CY2022Q1 us-gaap Goodwill Translation And Purchase Accounting Adjustments
GoodwillTranslationAndPurchaseAccountingAdjustments
0
CY2022Q1 us-gaap Goodwill
Goodwill
14608000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6331000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6214000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59583000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
60419000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
65914000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
66633000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
800000
CY2022Q1 us-gaap Sublease Income
SubleaseIncome
800000
CY2021Q1 us-gaap Sublease Income
SubleaseIncome
600000
CY2022Q1 rvmd Tenant Improvement Allowance Credits
TenantImprovementAllowanceCredits
100000
CY2021Q1 rvmd Tenant Improvement Allowance Credits
TenantImprovementAllowanceCredits
100000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
700000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
5897000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6961000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7100000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7349000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7606000
CY2022Q1 rvmd Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
60422000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
95335000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28193000
CY2022Q1 rvmd Lessee Operating Lease Liability Tenant Improvement Allowance
LesseeOperatingLeaseLiabilityTenantImprovementAllowance
1228000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
65914000
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.061
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y7M6D
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote
CY2022Q1 rvmd Number Of Voting Rights Per Common Share
NumberOfVotingRightsPerCommonShare
1
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18337494
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13967835
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
58700000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6644000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3387000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-57647000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-37176000
CY2022Q1 rvmd Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
74183111
CY2021Q1 rvmd Weighted Average Number Of Shares Issued Basic And Diluted
WeightedAverageNumberOfSharesIssuedBasicAndDiluted
70534554
CY2022Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
20748
CY2021Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
114478
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
74162363
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70420076
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9215547
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6434432

Files In Submission

Name View Source Status
0000950170-22-008496-index-headers.html Edgar Link pending
0000950170-22-008496-index.html Edgar Link pending
0000950170-22-008496.txt Edgar Link pending
0000950170-22-008496-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvmd-20220331.htm Edgar Link pending
rvmd-20220331.xsd Edgar Link pending
rvmd-20220331_cal.xml Edgar Link unprocessable
rvmd-20220331_def.xml Edgar Link unprocessable
rvmd-20220331_htm.xml Edgar Link completed
rvmd-20220331_lab.xml Edgar Link unprocessable
rvmd-20220331_pre.xml Edgar Link unprocessable
rvmd-ex10_1.htm Edgar Link pending
rvmd-ex10_2.htm Edgar Link pending
rvmd-ex10_3.htm Edgar Link pending
rvmd-ex31_1.htm Edgar Link pending
rvmd-ex31_2.htm Edgar Link pending
rvmd-ex32_1.htm Edgar Link pending
rvmd-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending